Background: Juvéderm Ultra injectable gel (Allergan, Inc, Irvine, California) is approved in the United States to treat moderate to severe wrinkles and folds, such as nasolabial folds. It is also used to enhance the appearance of the lips. Objectives: The authors evaluated the safety and effectiveness of Juvéderm Ultra injectable gel for lip enhancement and assessed the utility of 3 new lip-specific effectiveness scales. Methods: In this multicenter study, 50 subjects received lip enhancement with Juvéderm Ultra injectable gel. The subjects were observed closely by the treating investigator and results were evaluated by a blinded independent rater and by subject self-assessment for up to 48 weeks to determine the durability of the effects. A validated lip fullness scale (LFS) was used for analysis. Treatment satisfaction was assessed by investigators and subjects using an 11-point scale. Results: At week 12, 71% of subjects had achieved their goals for lip fullness and had maintained improvement of at least 1 grade on the LFS, which greatly exceeded the a priori criterion of 40% for success. At week 24, improvement in lip fullness was still present for 56% of subjects. Satisfaction and goal achievement exceeded 90% for subjects as well as investigators. Common side effects were predominantly mild or moderate in intensity and resolved within 1 week in the majority of subjects. Conclusions: Juvéderm Ultra injectable gel is safe and effective for lip enhancement. Scales for assessing lip fullness provide an objective method to determine the effectiveness of treatment.
The lips and perioral area, which are among the focal points for overall rejuvenation of the aging face, can be addressed by cosmetic medicine procedures. Many patients desire such treatment to increase fullness and minimize wrinkles in these areas, particularly the lips. An abundance of recent literature has focused on the essential issues that patients and practitioners face with regard to overall aesthetic analysis and goals, [1] [2] [3] [4] treatment options (including the various agents for lip enhancement), [5] [6] [7] [8] [9] and handling of complications if they arise. 6 Various assessment scales have been formulated and validated to aid in the objective evaluation of cosmetic treatments for the lips. [10] [11] [12] [13] As new treatment products have become available, the nuances of their particular use in on-label and off-label facial regions have become more apparent, particularly as greater experience is gained with the products. Therefore, the new metric tools can be useful in clinical research and clinical practice as barometers of success and to facilitate comparisons between products.
Juvéderm Ultra injectable gel (Allergan, Inc, Irvine, California) and other hyaluronic acid (HA) gels have achieved immense popularity in recent years, and their use has expanded beyond the approved indication of "correction of moderate to severe facial wrinkles and folds," for which extensive clinical trial data are available.
14 When the present Investigational Device Exemption study was being developed, there were few published trials of HA fillers for the lips. Within this landscape, the current study was designed to assess Juvéderm Ultra for lip enhancement.
MEthOds
This multicenter study was designed to evaluate the safety and effectiveness of Juvéderm Ultra injectable gel for lip enhancement and to confirm the utility of 3 new scales to assess the effectiveness of treatment. 12, 13 Prior to study initiation, approval was obtained from the Institutional Review Board of each of the 8 US investigational sites. Written informed consent was provided by all subjects.
Subjects
To be eligible for participation, subjects were required to be at least 18 years old, have a lip fullness score (LFS) of "minimal" or "mild" on a 4-grade scale (minimal, mild, moderate, marked), and have a lip fullness goal that was deemed to be achievable by the treating investigator. Subjects were excluded if they had significant asymmetry in the lip or perioral area, had a "severe" oral commissure severity (OCS) score, had ever received semipermanent or permanent implants in the face or neck, or had undergone any of the following procedures within 6 months of study entry: cosmetic facial procedure, tissue augmentation in the face or neck, or injection of BOTOX Cosmetic (Allergan, Inc), which was the only Food and Drug Administrationapproved botulinum toxin for aesthetic use at the time of study enrollment in 2007, in the lower face.
Treatment and Evaluations
All study treatments were administered between August 24, 2007, and October 9, 2007 . Each subject received Juvéderm Ultra injections in 1 or more perioral areas for lip enhancement: vermilion (red portion of lip), vermilion borders, Cupid's bow, philtral columns, and oral commissures. A maximum of 4 syringes (total of 3.2 mL) were allowed for each subject (initial treatment plus an optional touchup 2 weeks later). A sham/saline injection arm was not included because it would have been obvious to the injector, subject, and evaluator that this was not active treatment. Moreover, the injection could have damaged the lips while providing no benefit to the subject.
Follow-up evaluations were performed at 2, 6, 12, 18, and 24 weeks following the last injection, during the primary phase of the study. An extended phase allowed for follow-up visits at 30, 36, 42, and 48 weeks after the last treatment, until each subject's lips returned to her or his pretreatment (baseline) appearance.
Investigator and subject assessments were performed before treatment and at each follow-up visit. As part of the evaluation, standardized 3-dimensional (3D) digital images were obtained of each subject's face. Prior to treatment, subjects used the validated photographic lip LFS 12 to assess their current lip fullness (minimal, mild, moderate, or marked) and their goal for lip fullness. Subjects maintained diaries for 2 weeks following each treatment for the purpose of recording the occurrence, severity, and duration of treatment-site effects.
At each study site, assessments were performed by the treating investigator and by an independent "evaluating investigator" who was blinded to the volume and location of treatments and to previous assessment scores. The blinded investigators were included to reduce potential bias in the evaluation of outcomes. They provided assessments without knowledge of the subjects' treatment goals or the specific areas of treatment.
A video of the senior author's technique is available at www.aestheticsurgeryjournal.com. You may also use your smartphone to scan the code below to be taken directly to the video at www.YouTube.com.
Outcome Measures and Statistical Analyses
The primary effectiveness measure was 2-fold and consisted of (1) appearance of the subject's lips on the 4-grade LFS and (2) the subject's assessment of whether the treatment goal for lip fullness was achieved. Subjects who demonstrated an increase in lip fullness of ≥1 grade from baseline and whose LFS treatment goal was achieved were considered "responders." A responder rate of 40% at week 12 was established, a priori, as the requirement for attaining clinical effectiveness.
Other effectiveness measures included investigator assessments of perioral lines (POL) and oral commissures using validated 4-grade photographic scales (none, mild, moderate, severe) 13 and subject assessments of lip fullness, POL, and OCS. Satisfaction was assessed on an 11-point scale by investigators and subjects (Table 1) , with the highest 4 points (7-10) denoting "very satisfied." Investigator satisfaction was assessed separately for the subject's mouth area in repose and in animation.
For the 3D digital images, each subject bit on a sheet of warm dental wax at the initial visit (prior to treatment), from which a mold of the inside of the mouth was created. The mold was used at all subsequent visits to ensure consistent positioning of the teeth and jaw. Lips were placed in the closed position for these photographs because that is the most natural position. Volume changes were calculated using software (Canfield Scientific, Fairfield, New Jersey) that incorporated results from before-and-after images, aligned to various facial landmarks.
Safety was evaluated from the common treatment-site responses (CTR) documented by subjects in the diaries they completed for the 2 weeks following each treatment, adverse events (AE), subject self-assessments of function and sensation of the lips and mouth area, and investigator assessments of the functional features of the lips and mouth area. Note that CTR lasting beyond 2 weeks were automatically classified as AE by investigators, who could also classify other CTR recorded by subjects as an AE, depending not just on duration but also severity. Subjects completed daily diaries with checkboxes for the CTR of redness, pain, tenderness (to touch), firmness, swelling, lumps/bumps, bruising, itching, discoloration (not redness or bruising), and other (specify).
A 2-sided exact binomial test was used to demonstrate clinical effectiveness for the primary end point, with significance set at a P value of .05. All other results were summarized using descriptive statistics.
REsuLts
Fifty subjects met the inclusion criteria and received Juvéderm Ultra for lip enhancement. All 50 subjects remained in the study throughout the 24-week primary phase, and 46 subjects (92%) completed the extended follow-up phase. All 50 subjects continued in the study through week 24, but some subjects missed some visits, and the percentages and citations in the Results section are based on those subjects actually assessed at a given time point. Most of the subjects were women (96%) of Caucasian descent (88%) with Fitzpatrick skin type II or III (80%), but all skin types were represented. The median age at study entry was 47 years (range, 24-68 years).
Eighteen of the 50 subjects (36%) received a touchup treatment after their initial procedure. All injections were performed with a needle (usually a 30-gauge device). The median injection volume was 1.6 mL for the initial treatment (range, 0.65-3.2 mL) and 0.6 mL for the touchup procedure (range, 0.1-1.6 mL). Slightly more volume was injected into the upper lip (initial treatment median: 0.7 mL [range, 0.3-1. All subjects received treatment in the upper lip vermilion border. Most subjects also received treatment in the lower lip vermilion border, the upper and lower vermilion, Cupid's bow, and the oral commissures. The philtral columns were treated in one-third of the subjects (Table 2) . Subdermal was the most frequent injection plane for the vermilion border, vermilion, and Cupid's bow, whereas intradermal was the most common plane for philtral columns and oral commissures (Table 3) . Retrograde tunneling was used most frequently during initial treatments (80% of subjects), followed by antegrade tunneling (48%), serial puncture (40%), cross-hatching (34%), and fanning (18%). Cross-hatching and fanning were used exclusively for oral commissures. 
Effectiveness
The primary end point was attained: 71% of subjects achieved their goal for lip fullness, and improvement of ≥1 grade on the LFS was maintained through 12 weeks. Therefore, based on the a priori definition of success (responder rate of 40%), clinical effectiveness was achieved. Furthermore, when subjects were stratified by baseline and treatment characteristics, clinical effectiveness also was demonstrated for each subgroup (ie, pretreatment lip fullness, subject age, volume injected, injection site, injection plane, and injection technique). The goal for lip fullness was achieved for almost all subjects; 96% of evaluating investigators and 94% of subjects noted that the goal was achieved at week 2. At baseline, the evaluating investigators rated lip fullness as minimal for 15 subjects (30%), mild for 32 subjects (64%), and moderate for 3 subjects (6%). Because the lip fullness of the latter 3 subjects had been rated as minimal or mild by the treating investigators, these subjects were eligible for the study. Two weeks after the last treatment, lip fullness had improved substantially. At that time, there were no minimal ratings, 7 (14%) mild ratings, 28 (56%) moderate ratings, and 15 (30%) marked ratings. At the week 12 visit, no subject's lips had regressed to minimal fullness. Fifteen (31%) had mild fullness, 24 (49%) had moderate fullness, and 10 (20%) had marked fullness. By week 24, 5 subjects (10%) had minimal fullness, 18 (38%) had mild fullness, 20 (42%) had moderate fullness, and 5 (10%) had marked fullness.
At week 12, 80% of subjects (39 of 49) showed LFS improvement of ≥1 grade, and this improvement was maintained for the majority of subjects (27 of 48, 56%) through week 24. After week 24, subjects were discontinued from the study once their lip fullness returned to the baseline score. The results for weeks 30 to 48 include these discontinued subjects in the denominator of the calculations to appropriately capture them as no longer having LFS improvement (Figure 1) . By week 36, less than half of the subjects (40%) still showed improvement in lip fullness versus baseline assessments.
Although the vertical lines of the upper lips were not injected in this study, the evaluating investigators' ratings showed that POL scores improved ≥1 grade from baseline for 51% of subjects (25 of 49 subjects) at week 12 and for 46% of subjects (22 of 48) at week 24. The OCS scores improved ≥1 point from baseline for 64% of subjects (27 of 42) at week 12 and for 59% of subjects (25 of 42) at week 24. Similar patterns of improvement were observed for LFS, POL, and OCS by the subjects and treating investigators. Calculations from the 3D digital images provided objective confirmation of the observed increases in lip fullness. Lip volume increased by a mean of 0.94 cm 3 at week 2, which was sustained through week 12 (0.74 cm 3 ) and week 24 (0.73 cm 3 ). Lip surface area increased by a mean of 34% at week 2, 27% at week 12, and 25% at week 24. Upper lip projection increased by 40% at week 2, by 31% at week 12, and by 21% at week 24. Lower lip projection increased by 31% at week 2, by 30% at week 12, and by 24% at week 24. Examples of the lip fullness achieved and maintained in study participants, including an overlay 3D image combining views at baseline and week 2, are shown in Figures 2 and 3 .
The evaluating investigators' ratings of overall satisfaction with the aesthetic features of the subjects' lips and mouth improved following treatment. At baseline, only 42% were very satisfied with the perioral area in both repose and animation. At week 2, 96% were very satisfied with the mouth area in repose, and 98% were very satisfied with the animated position. Satisfaction remained high through week 24 (Figure 4) . With respect to overall subject satisfaction with the effect of study treatment, 92% were very satisfied at week 2, which was sustained for 82% at week 12 and for 81% at week 24.
Safety
The most frequent CTR recorded in subject diaries were swelling (94% of subjects), bruising (92%), and tenderness (88%). These were predominantly mild or moderate and resolved within 1 week for the majority of subjects. Again, CTR lasting beyond 2 weeks were classified as AE. Sixteen subjects (32%) experienced AE attributed to the device, most commonly injection-site nodules (lumps/bumps) and induration (firmness). These AE, which generally lasted 2 to 3 weeks, resolved without intervention. Other AE attributed to the device included bruising, edema, and pain. Subject assessments showed that most participants did not experience any adverse effects in lip function or sensation. Investigator assessments also demonstrated that lip functionality was not compromised by the study treatment.
disCussiOn
In many ways, the results of this study mirror what is observed in clinical practice. The study showed a very high rate of satisfaction with Juvéderm Ultra injectable gel for the indication of lip enhancement, corroborated by the subject, treating physician, and blinded evaluator, with good concordance. The majority of subjects maintained clinically significant (≥1 grade on the LFS) improvement in lip fullness through 6 months. These improvements were confirmed, with a high level of consistency, by the objective analysis of 3D images. The objective measurements from the 3D images substantiated the observations of the unblinded investigators and the subjects and helped to compensate for the study's lack of a control group. Another limitation of the study was that LFS ratings were based on the overall appearance of both lips; the upper and lower lips were not evaluated separately.
The maximum allowable volume of filler used in the present study (3.2 mL for the entire perioral area) is consistent with that of the pivotal lip study of Restylane 15 (Medicis Aesthetics, Scottsdale, Arizona) and the subsequent Although no occlusive events were observed in the current study, this is a risk with any filler injection. Practitioners should make patients aware of this risk and should know how to remedy this potential complication. One advantage of HA is the availability of hyaluronidase, which can be used if this problem arises. 17 Consistent with clinical practice, very few AE occurred in this study. Most of these events were of mild or moderate severity and resolved within 1 week.
Although the number of touchup treatments in the present study was higher than what is typical in clinical practice, this likely resulted from the study's requirement for frequent follow-up visits and the absence of patient costs for study treatment. It is also possible that the treating investigators might have been more conservative in their initial treatment (vs typical clinical practice) because they knew that they would have the opportunity to optimize the effect with a touchup procedure.
COnCLusiOns
Juvéderm Ultra injectable gel is an effective and safe agent for lip enhancement. Scales for assessing lip fullness provide an objective method to determine the effectiveness of treatment. In addition to serving as an objective metric in clinical studies, 3D imaging is a potential tool to help physicians improve patient care through better understanding of the volumetric effects of cosmetic treatments and overall lip aesthetics.
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